Integrating Immune Therapies & Targeted Therapies Into Standards of Care for Hematologic and Solid Malignancies
WebcastOVERVIEW
Integrating Immune Therapies & Targeted Therapies Into Standards of Care for Hematologic and Solid Malignancies is organized by Biomedical Learning Institute (BMLI) and will be held from Jan 01, 2018 - Jan 01, 2019. This CME Conference has been approved for a maximum of 8.75 AMA PRA Category 1 Credits.
Target Audience:
This activity is designed to meet the educational needs of medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, oncology pharmacists, oncology nurses/Advanced Nurse Practitioners, and other allied healthcare professionals involved in the treatment, care and management of patients with solid and hematologic malignancies that are responsive to immune and targeted therapies. Cancer Is treated optimally by a multi-disciplinary approach of clinicians, and thus, all of the aforementioned clinical specialties are targeted for invitation to this CME/CE activity.
Learning Objectives:
• Understand how to apply the different various approved and emerging immune therapy strategies for NSCLC patients in the treatment naïve and salvage settings.
• Compare and contrast the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
• Evaluate the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
• Analyze the new and existing strategies including immune therapy, novel chemotherapy and targeted therapy for patients with squamous NSCLC across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
• Evaluate the large number of open clinical trials offering various combinations of immune and targeted therapies for NSCLC and Head & Neck cancer as possible options for enrolling eligible patients to possibly improve outcome.
• Compare and contrast the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
• Understand when and how to use liquid biopsies versus larger gene panels to help guide serial biopsies when there is insufficient tissue available.
Additional details will be posted as soon as they are available.
Target Audience:
This activity is designed to meet the educational needs of medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, oncology pharmacists, oncology nurses/Advanced Nurse Practitioners, and other allied healthcare professionals involved in the treatment, care and management of patients with solid and hematologic malignancies that are responsive to immune and targeted therapies. Cancer Is treated optimally by a multi-disciplinary approach of clinicians, and thus, all of the aforementioned clinical specialties are targeted for invitation to this CME/CE activity.
Learning Objectives:
• Understand how to apply the different various approved and emerging immune therapy strategies for NSCLC patients in the treatment naïve and salvage settings.
• Compare and contrast the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
• Evaluate the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
• Analyze the new and existing strategies including immune therapy, novel chemotherapy and targeted therapy for patients with squamous NSCLC across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
• Evaluate the large number of open clinical trials offering various combinations of immune and targeted therapies for NSCLC and Head & Neck cancer as possible options for enrolling eligible patients to possibly improve outcome.
• Compare and contrast the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
• Understand when and how to use liquid biopsies versus larger gene panels to help guide serial biopsies when there is insufficient tissue available.
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links